Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study DisappointsBenzinga • 07/06/21
Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe PneumoniaGlobeNewsWire • 07/06/21
Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides PatientsBenzinga • 06/22/21
Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company StrategyGlobeNewsWire • 06/16/21
Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual MeetingGlobeNewsWire • 06/10/21
New Lacutamab Data From Tellomak Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant LymphomaGlobeNewsWire • 06/09/21
Innate Pharma S.A. (IPHYF) CEO Mondher Mahjoubi on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business UpdateGlobeNewsWire • 05/04/21
Innate Pharma Files its 2020 Universal Registration Document (Document d'Enregistrement Universel) and 2020 Annual Report on Form 20-FGlobeNewsWire • 04/28/21
Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021GlobeNewsWire • 04/21/21
Innate Pharma announces conference call and webcast for Full Year 2020 financial resultsGlobeNewsWire • 03/16/21
Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/17/21
Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma PatientsBenzinga • 02/09/21
Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell LymphomasGlobeNewsWire • 02/03/21
Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for DevelopmentGlobeNewsWire • 01/05/21
IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff Deadline: December 22, 2020Newsfile Corp • 12/22/20
Innate Pharma, S.A.: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law FirmGlobeNewsWire • 12/22/20
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmPRNewsWire • 12/22/20